Form 4: Bolt Biotherapeutics COO Awarded 30,000 RSUs

Bolt Biotherapeutics' Chief Operating Officer, Grant Yonehiro, was awarded 30,000 restricted stock units, vesting in full by September 2026.

Summary

• Grant Yonehiro, Chief Operating Officer of Bolt Biotherapeutics, Inc. (BOLT), was awarded 30,000 restricted stock units (RSUs) on October 22, 2025.
• The RSUs were received as an award for no consideration, meaning they were granted as part of compensation.
• Each restricted stock unit represents the right to receive one share of common stock upon settlement.
• Following this transaction, Mr. Yonehiro beneficially owns a total of 38,918 shares directly.
• The awarded RSUs will vest in full on September 15, 2026, contingent upon Mr. Yonehiro's continued employment through that date.

Sentiment

Score: 7

Explanation: The filing reports a routine executive compensation event, indicating stability in management and a standard approach to incentivizing key personnel. It's a neutral to slightly positive signal as it suggests retention efforts.

Positives

• Grant Yonehiro, the Chief Operating Officer, received an award of 30,000 restricted stock units, which aligns his long-term interests with those of the shareholders.
• The equity award demonstrates a commitment to retaining and incentivizing key management personnel.

Risks

• The vesting of the 30,000 restricted stock units is contingent upon Grant Yonehiro's continued employment through September 15, 2026, introducing a condition to the full realization of the award.

Future Outlook

The filing indicates a future vesting event for 30,000 restricted stock units on September 15, 2026, contingent on the Chief Operating Officer's continued employment.

Industry Context

This is a standard equity compensation event for a biotechnology company executive, common for retaining talent and aligning executive incentives with long-term company performance within the industry.

Comparison to Industry Standards

• Equity awards like Restricted Stock Units (RSUs) are a common form of executive compensation in the biotechnology and pharmaceutical sectors, used to attract, retain, and incentivize key personnel.
• The vesting schedule, contingent on continued employment, is typical for such awards, aiming to ensure long-term commitment.
• The grant of 30,000 RSUs to a Chief Operating Officer is within the expected range for a company of Bolt Biotherapeutics' size and stage, comparable to similar awards seen at peer companies in the pre-commercial or early-commercial biotech space.

Stakeholder Impact

• Shareholders: The award aligns the COO's interests with long-term shareholder value creation, as the value of the RSUs is tied to the company's stock performance. It also represents potential future dilution upon vesting.
• Employees: May signal stability in executive leadership and a commitment to retaining key talent.

Next Steps

• The restricted stock units will vest in full on September 15, 2026, assuming continued employment.

Key Dates

Recommendation

This Form 4 filing details a routine equity compensation award to a key executive. While it aligns management's interests with shareholders and indicates retention efforts, it does not provide new information regarding the company's operational performance, strategic direction, or financial health that would warrant a change in investment thesis. Therefore, a 'hold' recommendation is appropriate, maintaining current positions while awaiting more substantive operational or financial updates.

Keywords

Bolt Biotherapeutics, BOLT, Restricted Stock Units, RSU, Equity Award, Executive Compensation, Grant Yonehiro, COO, Insider Transaction, Form 4